Studying the effects of drugs on the metabolome constitutes a huge part of the metabolomics
discipline. Whether the approach is associated with drug discovery (altered pathways due to the disease
that provide future targets and information into the mechanism of action or resistance, etc.) or pharmacometabolomics
(studying the outcome of treatment), there have been many aspiring published articles
in this area. With specific experimental design, including fingerprinting analysis with different analytical
platforms in a non-targeted way, the approach is advancing towards the discovery of markers for the implication of personalised
medicine, while also providing information that could help to improve the efficacy and reduce the side effects
associated with a treatment. In this review, the evolution of pharmacometabolomics from other areas of drug efficacy metabolomics
studies is explored.
Keywords: Biomarker, Drug discovery and development, Metabolomics, Personalised medicine, Pharmacometabolomics.
Rights & PermissionsPrintExport